Abeona Therapeutics Inc.: investing cash flow
Abeona Therapeutics investing cash flow: $105.0 million for the year ending 2025-12-31, up 367.7% on the year. 14 values since 2010. In original units.
All Abeona Therapeutics Inc. financial histories
At a glance
Abeona Therapeutics reported investing cash flow of $105.0 million for the year ending 2025-12-31, up 367.7% from -$39.2 million a year earlier. Across the last five reported years it ranged from -$39.2 million (2024-12-31) to $105.0 million (2025-12-31). That was 1804.6% of revenue ($5.82 million) for the same year.
Computed from the values in the table below, in USD; each links to the filing it came from.
What this measure means
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
Exact concept: us-gaap:NetCashProvidedByUsedInInvestingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 105,028,000 | USD | 2026-03-17 | 10-K · 0001493152-26-010413 SEC |
| 2024-01-01 | 2024-12-31 | -39,240,000 | USD | 2026-03-17 | 10-K · 0001493152-26-010413 SEC |
| 2023-01-01 | 2023-12-31 | 208,000 | USD | 2025-03-20 | 10-K · 0001493152-25-010978 SEC |
| 2022-01-01 | 2022-12-31 | -23,964,000 | USD | 2024-03-18 | 10-K · 0001493152-24-010190 SEC |
| 2021-01-01 | 2021-12-31 | 66,062,000 | USD | 2023-03-29 | 10-K · 0001493152-23-009381 SEC |
| 2020-01-01 | 2020-12-31 | -83,714,000 | USD | 2022-03-31 | 10-K · 0001493152-22-008259 SEC |
| 2019-01-01 | 2019-12-31 | 59,976,000 | USD | 2021-03-24 | 10-K · 0001493152-21-006705 SEC |
| 2018-01-01 | 2018-12-31 | -85,086,000 | USD | 2020-03-16 | 10-K · 0001493152-20-004015 SEC |
| 2017-01-01 | 2017-12-31 | -860,000 | USD | 2020-03-16 | 10-K · 0001493152-20-004015 SEC |
| 2016-01-01 | 2016-12-31 | -519,000 | USD | 2019-03-18 | 10-K · 0001144204-19-014623 SEC |
| 2013-01-01 | 2013-12-31 | -2,000 | USD | 2014-03-26 | 10-K · 0000318306-14-000006 SEC |
| 2012-01-01 | 2012-12-31 | -13,000 | USD | 2014-03-26 | 10-K · 0000318306-14-000006 SEC |
| 2011-01-01 | 2011-12-31 | -40,000 | USD | 2013-03-20 | 10-K · 0000318306-13-000004 SEC |
| 2010-01-01 | 2010-12-31 | -7,000 | USD | 2012-03-23 | 10-K · 0000318306-12-000020 SEC |
Related ABEONA THERAPEUTICS INC. histories
Inspect the source
- Entity
- ABEONA THERAPEUTICS INC. / CIK 0000318306
- Captured
- SEC response SHA-256
636768f46653d2a6ef88c7a2f3600aa36414b265029032bf07e61c32ce5542a2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000318306.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))